Congressional Testimony 2016

This section includes testimony by FDA officials before House and Senate Committees and Subcommittees.

December 2016

• 12/07/2016: Waste and Duplication in the USDA Catfish Inspection Program 
  William R. Jones, Ph. D, before the Committee on Energy and Commerce, U.S. House of Representatives

September 2016

• 09/22/2016: Exploring a Right to Try for Terminally Ill Patients 
  Peter Lurie, M.D., M.P.H., before the Committee on Homeland Security and Government Affairs, U.S. Senate
• 09/21/2016: Reviewing the Rising Price of EpiPens 
  Douglas Throckmorton, M.D., before the Committee on Oversight and Government Reform, U.S. House of Representatives
• 09/21/2016: Prioritizing Public Health: The FDA’s Role in the Generic Drug Marketplace 
  Janet Woodcock, M.D., before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies; Committee on Appropriations; U.S. Senate

July 2016

• 07/13/2016: Researching the Potential Medical Benefits and Risks of Marijuana 
  Douglas Throckmorton, M.D., before the Committee on the Judiciary, U.S. Senate

June 2016

• 06/14/2016: Examining Ways to Combat Antibiotic Resistance and Foster New Drug Development 
  Janet Woodcock, M.D. before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
• 06/07/2016: Deadly Synthetic Drugs: The Need to Stay Ahead of the Poison Peddlers 
  Douglas Throckmorton, M.D., before the Committee on the Judiciary, U.S. Senate

May 2016

• 05/19/2016: Strengthening Public Health Emergency Response Act of 2015 
  Michael Mair, MPH, before the House Subcommittee on Health, Committee on Energy

April 2016

• 04/20/2016: How Secure are U.S. Bioresearch Labs? Preventing the Next Safety Lapse 
  Segaran Pillai, Ph.D., before the House Energy and Commerce Committee, Subcommittee on Oversight and Investigations

March 2016

• 03/02/2016: Examining the U.S. Public Health Response to the Zika Virus 
  Luciana Borio, M.D., before the House Energy and Commerce Committee, Subcommittee on Oversight and Investigations
• 03/02/2016: President's Fiscal Year 2017 Budget Request (Senate) 
  Robert Califf, M.D., before the Senate Appropriations Committee, Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies

February 2016

• 02/25/2016: President's Fiscal Year 2017 Budget Request (House) 
  Stephen Ostroff, M.D., before the Committee on Appropriations; Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies; U.S. House of Representatives
• 02/04/2016: Biosimilars Implementation 
  Janet Woodcock, M.D., before the House Committee on Energy and Commerce, Subcommittee on Health
• 02/04/2016: Implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA) 
  Janet Woodcock, M.D., before the House Committee on Oversight and Government Reform

January 2016

• 01/28/2016: Implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA) 
  Janet Woodcock, M.D., before the Senate Committee on Health, Education, Labor and Pensions